Literature DB >> 8178474

Interaction of poliovirus with its cell surface binding site.

J A Bibb1, G Witherell, G Bernhardt, E Wimmer.   

Abstract

The interaction of poliovirus with its cellular binding sites was characterized by using a receptor-excess silicon oil partition assay. Poliovirus type 1 Mahoney [PV1(M)] binding to HeLa cells fits a theoretical simple bimolecular noncooperative binding curve with an equilibrium dissociation constant (Kd) of 4.3 x 10(7) cells.ml-1 at 4 degrees, or 2.1 x 10(-10) M, assuming 3000 virus binding sites/cell. The association rate of complex formation was measured to be 3.6 x 10(-9) ml.cell-1.min-1 (7.2 x 10(8) M-1.min-1) and the dissociation rate calculated to be 1.5 x 10(-1) min-1, giving the complex a half-life of 4.5 min. The equilibrium dissociation constant, association rate, and dissociation rate were also measured for the binding of the attenuated poliovirus type 3 Sabin strain [PV3(S)] to HeLa cells. PV3(S) bound HeLa cells with a Kd of 3.3 x 10(7) cells.ml-1 (1.6 x 10(-10) M), an association rate of 4.1 x 10(-9) ml.cell-1.min-1 (8.2 x 10(8) M-1.min-1), and a dissociation rate calculated to be 1.4 x 10(-1) min-1, giving the complex a half-life of 5.1 min. Thus the virulent and avirulent strains of poliovirus bind HeLa cells with nearly identical binding constants and rate constants. Equilibrium binding constants for PV1(M) to various other cell types varied from a high affinity of 4.1 x 10(6) cells.ml-1 for JA-1 cells to a low affinity of 7 x 10(7) cells.ml-1 for NGP cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8178474     DOI: 10.1006/viro.1994.1270

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  Consequences of a subtle sialic acid modification on the murine polyomavirus receptor.

Authors:  M Herrmann; C W von der Lieth; P Stehling; W Reutter; M Pawlita
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Interaction of poliovirus with its purified receptor and conformational alteration in the virion.

Authors:  M Arita; S Koike; J Aoki; H Horie; A Nomoto
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Binding kinetics of ecotropic (Moloney) murine leukemia retrovirus with NIH 3T3 cells.

Authors:  H Yu; N Soong; W F Anderson
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

4.  CD46 short consensus repeats III and IV enhance measles virus binding but impair soluble hemagglutinin binding.

Authors:  P Devaux; C J Buchholz; U Schneider; C Escoffier; R Cattaneo; D Gerlier
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Particle agglutination method for poliovirus identification.

Authors:  Minetaro Arita; Souji Masujima; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Vis Exp       Date:  2011-04-20       Impact factor: 1.355

6.  Fast and high-affinity binding of B-lymphotropic papovavirus to human B-lymphoma cell lines.

Authors:  M Herrmann; M Oppenländer; M Pawlita
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Bacterial lipopolysaccharide binding enhances virion stability and promotes environmental fitness of an enteric virus.

Authors:  Christopher M Robinson; Palmy R Jesudhasan; Julie K Pfeiffer
Journal:  Cell Host Microbe       Date:  2014-01-15       Impact factor: 21.023

8.  The human poliovirus receptor alpha is a serine phosphoprotein.

Authors:  J A Bibb; G Bernhardt; E Wimmer
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Characterization of the New World monkey homologues of human poliovirus receptor CD155.

Authors:  Shaukat Khan; Xiaozhong Peng; Jiang Yin; Ping Zhang; Eckard Wimmer
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

10.  Characterization of cell-binding properties of bovine herpesvirus 1 glycoproteins B, C, and D: identification of a dual cell-binding function of gB.

Authors:  Y Li; S van Drunen Littel-van den Hurk; L A Babiuk; X Liang
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.